

RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

This study is a clinical research trial for the investigational medication KarXT (combination xanomeline-trospium). The trial will determine if KarXT is safe and effective in treating symptoms of schizophrenia in combination with another antipsychotic medication. Participants will continue to take the same dose of their current antipsychotic medication and will be randomly assigned to either take KarXT or a placebo. Individuals joining the study will receive compensation for their participation.

WHO CAN PARTICIPATE?

This study is seeking a total 400 participants. Participants may be eligible for this study if they:

- Are between the ages of 18 and 55
- Have a primary diagnosis of schizophrenia
- Have taken a first-line antipsychotic medication for at least six weeks and are still experiencing symptoms

Please note that these criteria are not complete. Certain other factors may disqualify an individual from participation. For a full list of inclusion and exclusion criteria, please visit the study description that can be found on the clinicaltrials.gov [website](https://clinicaltrials.gov/ct2/show/NCT05145413) (https://clinicaltrials.gov/ct2/show/NCT05145413) or go to the [ARISE study website](https://arise.researchstudytrial.com/) (https://arise.researchstudytrial.com/) that works with Karuna in assessing eligibility criteria and can provide information about nearby study centers.

WHERE IS THE STUDY TAKING PLACE?

The study will take place at approximately 36 study sites in the United States and 15 sites outside of the United States. More information about the study entry criteria and location of study sites can be found at the clinicaltrials.gov [website](https://clinicaltrials.gov/ct2/show/NCT05145413) (Please scroll down a few pages and click the tab "study location").

HOW DO I LEARN MORE?

The document(s) attached have additional information about the study. If you have questions or would like more information, please refer to our [ARISE study website](https://arise.researchstudytrial.com/). Other inquiries for Karuna can be sent as an email to medinfo@karunatx.com.